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Background: Plasmodium falciparum merozoites invade erythrocytes via interaction of a pathogen protein PfRh4 with a
host membrane receptor.
Results: The PfRh4-binding site on the human erythrocyte host receptor was mapped by mutagenesis and structural
methodology.
Conclusion: PfRh4 binds at the receptor terminus in a region overlapping a regulatory functional site.
Significance: Understanding the molecular basis of erythrocyte invasion will aid in design of therapeutics.
To survive and replicate within the human host, malaria par-
asites must invade erythrocytes. Invasion can be mediated by
the P. falciparum reticulocyte-binding homologue protein 4
(PfRh4) on the merozoite surface interacting with complement
receptor type 1 (CR1, CD35) on the erythrocytemembrane. The
PfRh4 attachment site lies within the three N-terminal comple-
ment control protein modules (CCPs 1–3) of CR1, which
intriguingly also accommodate binding and regulatory sites for
the key complement activation-specific proteolytic products,
C3b and C4b. One of these regulatory activities is decay-accel-
erating activity. Although PfRh4 does not impact C3b/C4b
binding, it does inhibit this convertase disassociating capability.
Here, we have employed ELISA, co-immunoprecipitation, and
surface plasmon resonance to demonstrate that CCP 1 contains
all the critical residues for PfRh4 interaction. We fine mapped
by homologous substitution mutagenesis the PfRh4-binding
site on CCP 1 and visualized it with a solution structure of CCPs
1–3 derived byNMRand small angle x-ray scattering.We cross-
validated these results by creating an artificial PfRh4-binding
site through substitution of putative PfRh4-interacting residues
from CCP 1 into their homologous positions within CCP 8;
strikingly, this engineered binding site had an 30-fold higher
affinity for PfRh4 than the native one in CCP 1. These experi-
ments define a candidate site on CR1 by which P. falciparum
merozoites gain access to human erythrocytes in a non-sialic
acid-dependent pathway of merozoite invasion.
Malaria continues to be a cause of significant disease burden
worldwide, with over 700,000 deaths annually (1).Most cases of
severe malaria are caused by Plasmodium falciparum. Sporo-
zoites released after the bite of a female Anopheles mosquito
travel via the bloodstream to the liver where they asexually
reproduce into thousands of merozoites. The latter subse-
quently target and infect erythrocytes, where they asexually
reproduce until the cell bursts to begin another merozoite
infective cycle. Fatalities are common, especially in children, as
a result of anemia or cerebral malaria, both of which occur
during the erythrocytic phase of the parasite’s life cycle (2). This
is also a stage susceptible to vaccine-based prophylaxis.
Although substantial efforts have been made to develop a vac-
cine, results have been largely disappointing (3, 4). A better
understanding at themolecular level of the interaction between
the P. falciparummerozoite and the host erythrocyte is impor-
tant for development of potential therapeutics (5).
The process whereby merozoites enter erythrocytes takes
only30 s and was visualized nearly four decades ago for Plas-
modium knowlesi and more recently for P. falciparum (6, 7),
but the mechanisms involved are still not fully understood. In
this multistep invasion process, parasite ligands first interact
with erythrocyte membrane proteins (8). Subsequently, a tight
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junction forms between amerozoite and the erythrocyte mem-
brane, which is triggered by and dependent on the initial recep-
tor-parasite ligand interaction (5, 9).
Chief among these parasite ligands aremembers of the eryth-
rocyte-binding-like antigens (5, 10, 11) and the reticulocyte-
binding homologue proteins (PfRh) (5, 12, 13). Several host
ligand protein pairs have been identified: glycophorin A:EBA-
175 (14, 15), glycophorin B:EBL-1 (16), glycophorin C:EBA-140
(17), Basigin:PfRh5 (18), and complement receptor type 1
(CR1,9 CD35):PfRh4 (19, 20). The CR1:PfRh4 pathway is the
major sialic acid-independent alternative to glycophorin-medi-
ated invasion (19, 20). PfRh4 engages the large ectodomain of
this single-pass membrane protein (21) to mediate a functional
invasion pathway by P. falciparum parasites (20). CR1 is an
250-kDa type 1membrane glycoprotein that is also known as
the C3b/C4b receptor or immune adherence receptor (22–27).
CR1 is displayed on primate peripheral blood cells including
erythrocytes but is not produced by platelets or most T cells.
Erythrocyte CR1 binds particles opsonized with C3b and/or
C4b and transports them to the liver and spleen for destruction
and to initiate an adaptive immune response. Population
groups and rare individuals with low (100) CR1 copy number
expression on erythrocytes have been identified, but no individ-
ual with a complete deficiency has been reported (28, 29). CR1
also regulates the complement cascade by multiple mecha-
nisms. It accelerates the dissociation or decay of C3 and C5
convertases that assemble after triggering of the alternative,
classical, or lectin pathways of complement activation. The
convertases cleave C3 and C5 to yield C3a and C5a (potent
proinflammatory anaphylatoxins), C3b (an opsonin and initia-
tor of a positive feedback amplification loop), and C5b (triggers
formation of the membrane attack complex). Furthermore,
CR1 serves as a cofactor for the factor I-mediated limited cleav-
age of C4b and C3b molecules that have become covalently
attached to a target, producing smaller fragments that are no
longer able to participate in complement activation cascades.
Subsequently, the covalently attachedC3membrane fragments
resulting from cofactor activity, iC3b and C3dg, can serve as
ligands for other complement receptors including CR2, CR3,
and CR4.
The CR1 gene lies within the regulators of complement acti-
vation cluster at 1q32 (30–33). Like other regulators of comple-
ment activation family members (34), it is predominantly com-
posed of multiple compact -sheet rich domains named
complement control protein modules (CCPs) (also called sushi
domains or short consensus repeats) (35). Thirty suchmodules
comprise the entire ectodomain of the most common size
(250 kDa) variant of CR1 (see Fig. 1). The CCPs, each consist-
ing of 59–72 residues, mediate the interactions between CR1
and its ligands. TheN-terminal 28 CCPs fall into four groups of
seven sequential CCPs, called long homologous repeats (LHRs
A–D), based on a high degree of internal sequence similarity
(36, 37). These modules are linked like beads on a string by
between four and eight amino acid residues.Within LHRs A, B,
and C, the first three CCPs are required tomediate interactions
with C3b or C4b and are also required for convertase decay
accelerating and factor I cofactor activity (36–44). We previ-
ously observed that CCPs 1–3 (called functional site 1) are nec-
essary and sufficient for binding to PfRh4 (21). Although bind-
ing of PfRh4 did not block C3b or C4b binding, it severely
curtailed the ability of CCPs 1–3 to accelerate the decay of the
AP and CP C3 convertases (21).
Employing the strategy of homologous substitutionmutagene-
sis, we previously identified amino acids in CCPs 1–3 and CCPs
8–10 (duplicated in CCPs 15–17) necessary for C4b and C3b
binding and for the complement regulatory activities (38–44).
Further, we could convert a predominantly C4b-binding site to
a C3b-binding site (42) and modulate primate forms of CR1
relative to their binding specificities and regulatory activities
for these two opsonins (41).
In the current studies, we have mapped by mutagenesis the
PfRh4 binding site to the most N-terminal and membrane-dis-
tal CCP of the CR1 ectodomain. We further identified key
PfRh4-binding residues of CCP 1 usingmutagenesis and placed
them in a structural context by solving the three-dimensional
structures of CCPs 1–3. These findings were further verified by
the design and creation of a soluble engineered version of a CR1
fragment with a 30-fold enhanced affinity for PfRh4 that is a
potential inhibitor of invasion. These studies will assist in the
development of new therapeutic agents as well as strategies to
prevent malaria.
EXPERIMENTAL PROCEDURES
Recombinant Proteins for Functional Studies: Synthesis, Puri-
fication, and Quantification—The full-length ectodomain of
CR1 (sCR1), produced in CHO cells, was a gift from Henry
Marsh (Celldex Therapeutics, Needham, MA). LHR A, B, C, D,
and D were prepared as previously described, employing
transfected human embryonic kidney 293T (HEK 293T) cells
(see Fig. 1) (39–43). LHR B and LHR C share 98% sequence
identity and were therefore utilized interchangeably (36–42).
In the same transfection system, we also prepared each individ-
ual LHR protein with a His6 tag on the C terminus to facilitate
purification using nickel-nitrilotriacetic acid-agarose beads
(Qiagen) following the manufacturer’s instructions. These
purified His-tagged samples were dialyzed against PBS and
concentrated. Additional mutants of LHR A, in which we
deleted either CCP 1, CCP 2, or CCP 3, were prepared as pre-
viously described (39, 42).
Mutations in which one or several amino acids were inter-
changedonaLHRAorLHRBtemplatewerepreparedwitheither
the QuikChange II or QuikChange lightning multi site-directed
mutagenesis kit (AgilentTechnologies).HEK293Tkidney epithe-
lial cells were routinely transfected using LipoD293 (SignaGen) in
serum-free media as per the manufacturer’s directions. Superna-
tants were collected after 48 h.
Recombinant CR1 proteins were quantified by sandwich
ELISA. In this procedure, 96-well flat-bottomed plates (Nunc)
were coated overnight at 4 °C with 100 l of rabbit polyclonal
anti-CR1 antibody (45) diluted to 4.2 g/ml in PBS. The plates
were blocked for 2 h at 37 °C with 1% (w/v) BSA and 0.1% (v/v)
9 The abbreviations used are: CR, complement receptor; CCP, complement
control protein; LHR, long homologous repeat; SAXS, small angle x-ray
scattering; IP, immunoprecipitation; RU, response units; PfRh4, P. falcipa-
rum reticulocyte-binding homologue protein 4.
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Tween 20 in PBS. CR1 samples and a calibrated standard (CCPs
15–25) (46) were added to the wells and incubated therein for
1 h at 37 °C. Then the plates were washed with PBS containing
0.05% (v/v) Tween 20 (PBS-T). Next, the detection antibody
diluted in PBS-T was added and incubated for 1 h at 37 °C
followed by washing with PBS-T. The murine detection anti-
bodies toCR1were: 7G9, provided byR. Taylor fromUniversity
of Virginia School of Medicine; 3D9, gifted by E. Brown at
Genentech Inc., now amember of the Roche group; J3B11, pro-
vided by J. Cohen from Hôpital Robert Debré; or E11, pur-
chased from Abcam. The HRP-conjugated anti-mouse IgG
(1:5,000 dilution; GE Healthcare) diluted in PBS-T was added
and incubated for 1 h at 37 °C followed by washing with PBS-T.
ortho-Phenylenediamine (100l) was used to detectHRP activ-
ity. After 30 min, the reaction was stopped with 100 l of 2 N
sulfuric acid, and optical density was measured at 490 nm.
Quantification of proteins was also performed using immobi-
lized J3B11 or the rabbit polyclonal Ab to CR1 in surface plas-
mon resonance and in Western blotting. The production and
purification of recombinant PfRh4 (Rh4.9), an 88-kDa protein
comprised of amino acid residues 28–766, which behaved sim-
ilarly to full-length PfRh4 (205 kDa) in its ability to bind to
erythrocytes, were performed as previously described (20, 47).
ELISA to Detect PfRh4 Interaction with CR1 Proteins—Ali-
quots of PfRh4 (100 l of 5 g/ml in PBS) were coated on
96-well flat-bottomed plates (Nunc). After an overnight incu-
bation at 4 °C, the plates were blocked as described above.
Serum-free supernatants from transfected cells or purified
recombinant His-tagged CR1 proteins (100 l each) diluted in
PBS-T containing 1% BSA and 1% Nonidet P-40 at a range of
concentrations (between 1 and 20 pM) were added to the wells
and incubated for 1 h at room temperature, and then the plates
were washed with PBS-T. Polyclonal anti-human CR1 Ab (100
l of 210ng/ml in PBS)was added and incubated for 1 h at room
temperature followed by washing with PBS-T. Next, HRP-con-
jugated donkey anti-rabbit IgG (100 l of a 1:5,000 dilution)
(GE Healthcare) was added and incubated for 1 h at room tem-
perature followed by washing. Detection was with ortho-phe-
nylenediamine as above. The means  S.E. are shown for all
samples, which were tested in duplicate in at least three inde-
pendent experiments.
Immunoprecipitation and Western Blotting—Serum-free
supernatants containing 1 g (in 200–500 l) of each CR1
construct were precleared, using 20 l of a 50% (w/v) slurry of
protein A/G-agarose (Thermo Scientific) and 0.5 g of mouse
IgG in PBS-T for 1 h at 4 °C. PfRh4 (2 g) was added to the
precleared supernatants of each CR1 sample and incubated
overnight at 4 °C. In separate tubes either 4 g of an anti-CR1
monoclonal Ab, J3B11, or 4 g of an anti-Rh4 monoclonal Ab,
10C9, were added to 20 l of protein A/G-agarose and prein-
cubated for 1 h at room temperature. The CR1:PfRh4 mixture
from above was then added to the antibody-bound beads and
incubated for an additional 2 h at room temperature. Beads
werewashed five timeswith PBS-T, and proteinswere eluted by
incubating with SDS nonreducing sample buffer for 5 min at
95 °C. Eluants were analyzed using 10% SDS-PAGE (Invitro-
gen) and transferred to a nitrocellulose membrane. Western
blotting for CR1 proteins was performed as follows: membrane
was blocked overnight at 4 °C with 5% (w/v) nonfat dry milk in
PBS-T. The blot was probed with rabbit anti-CR1 IgG (210
ng/ml diluted in blocking buffer) for 1 h at room temperature
followed by washing in PBS-T. A 1:5,000 dilution of HRP-con-
jugated donkey anti-rabbit IgG (GEHealthcare) was added and
incubated for 1 h at room temperature followed by washing in
PBS-T. The signals were visualized by utilizing enhanced
chemiluminescent substrate (Supersignal West Pico, Thermo
Scientific).Western blotting for PfRh4was performed similarly
using rabbit anti-Rh4 polyclonal antibody (5 g/ml in PBS-T).
Surface Plasmon Resonance—Experiments were performed
at 25 °C on a Biacore 2000 instrumentwith Biacore CM5 sensor
chips (GE Healthcare). Biosensor flow paths were activated
with a fresh 1:1 mixture of 0.05 M N-hydroxysuccinimide and
0.2 M ethyl-dimethylaminopropyl carbodiimide injected at 5
l/min for 7 min. Proteins were attached to the activated sur-
face in 10 mM citrate buffer, pH 4.8. The flow path was then
“blocked” by treatment with 1 M ethanolamine, pH 8.5, at 5
l/min for 10 min. Analytes were introduced at 20 l/min in
HEPES running buffer (10mMHEPES, 3mMEDTA, and 0.005%
Tween 20 at 150 mM NaCl) except as noted. Analyses of inter-
actions with immobilized recombinant CR1 samples employed
a reference flow path produced as above but without protein in
the citrate buffer. Analyses of interactions with immobilized
PfRh4 employed a reference flow path bearing immobilized
mouse IgG (Millipore). Data were analyzed using BIAevalua-
tion software version 4.1 (GE Healthcare). Dissociation con-
stants were calculated from Req values derived from reference-
subtracted curves and were fitted to a Langmuir 1:1 interaction
model. Nonlinear regression analyses andKD calculations were
made using GraphPad Prism software version 5.0.
NMR/SAXS-based Structural Determination of CR1 1,2, CR1
2,3, and CR1 1–3—A previously reported strategy (24, 46,
48–50) was deployed in which solution structures of overlap-
ping CCP pairs (CR1 1,2 and CR1 2,3) were solved by NMR and
then concatenated with the help of SAXS data (on CR1 1–3) to
generate a structure of the C3b/C4b-binding and PfRh4-
binding triple module N-terminal region of CR1 (amino
acids 1–192).
Double-labeled (13C,15N) samples of CR1 1,2 (0.56 mM) and
CR1 2,3 (0.80 mM) (produced from Pichia pastoris, essentially
as described previously (24)) were prepared in 20 mM sodium
acetate (deuterated) buffer at pH4.0 (CR1 1,2) or 10mMsodium
phosphate buffer at pH 6.0 (CR1 2,3) with 10% (v/v) D2O. Data
were collected at 25 °C (CR1 1,2) or 37 °C (CR1 2,3) on either
Avance 600 or Avance 800 MHz NMR spectrometers (Bruker)
(the lower temperature and pHused in the case of CR1 1,2 were
necessary to avoid proteolytic degradation). The standard suite
of two- and three-dimensionalNMRspectrawere collected and
processed using the software package AZARA. The assignment
of CR1 2,3 has already been described (51). The assignment of
CR1 1,2 was accomplished using similar techniques. The
assignment completeness of CR1 1,2 and CR1 2,3 is reported in
Table 1. All Pro residues were found in the trans form.
To generate distance restraints, three-dimensional 15N-ed-
ited NOESY and three-dimensional 13C-edited NOESY spectra
were collected and processed using AZARA in the CcpNmr
suite of programs (52). The NOEs and assignments of CR1 1,2
Binding Site of Malaria PfRh4 on Complement Receptor 1
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and CR1 2,3 were transferred from CcpNmr Analysis to
CYANA v. 2.1 (53) using the Format Converter software. Pre-
liminary structural calculations were carried out in CYANA
for both structures, until the published convergence. The
final NOEs were converted to the Xplor-NIH format using
the Format Converter.
Further structural calculations of CR1 1,2 and CR1 2,3 were
carried out in Xplor-NIH version 2.30 (54). In the first stage of
a simulated annealing protocol, the temperature was lowered
from an initial 2,000 K to 600 K in 50-K intervals, with 300 steps
of molecular dynamics at each temperature increment; within
this temperature interval, the energy terms (including the NOE
term and Ramachandran term) were progressively introduced
by multiplicative ramping. In the second stage, the structures
were cooled from 600 K to 100 K, in increments of 25 K, with
300 steps ofmolecular dynamics at each temperature; potential
terms (including the NOE term) were statically set to the top
values used in the first stage of cooling. One hundred structures
were calculated for each molecule.
A concatenated CR1 1–3 NOE list was created by merging
the CR1 1,2 and CR1 2,3 NOE lists. Only the NOEs from the
CR1 1–2 list that involve residues in (and between) CCP 1, the
CCP 1,2 linker, and the N-terminal half of the three-dimen-
sional structure of CCP 2 were used; the only NOEs extracted
for use from the CR1 2,3 list were those in (and between) the
C-terminal half of the three-dimensional structure of CCP 2,
the CCP 2,3 linker, and CCP 3. This procedure, similar to that
described previously (24, 49), was designed to remove potential
duplications and conflict involving the common CCP 2.
Structure calculations, incorporating the SAXS data for CR1
1–3 and the concatenated NOE list, were carried out in Xplor-
NIH version 2.30. A naive model of CR1 1–3, prepared using
MODELLER 9v10 (55) by overlaying closest tomean structures
of CR1 1,2 and CR1 2,3 on the common CCP 2, was used as a
starting structure. An identical protocol as for CR1 1,2 andCR1
2,3 was followed to calculate a refined structure of CR1 1–3,
with the exception that at all times an additional SAXS-derived
potential was used. In this calculation, 100 data points evenly
distributed in a cubic spline constructed using the SAXS data
were fitted against data back-calculated for the resulting struc-
tures using 500 solid angles.
Twenty structures (chosen based on the lowest overall
energy and structural convergence) of CR1 1,2, CR1 2,3, and
CR11–3were submitted forwater refinements.We included all
experimental and statistical potentials employed at the previ-
ous stage of structural calculations, using a standard Xplor-
NIH protocol. The resulting structures are summarized in Figs.
10 and 11 and in Table 1.
RESULTS
CCP 1 Is Required for PfRh4 Binding to CR1—We had previ-
ously mapped a PfRh4-binding site to CCPs 1–3 (functional
Site 1) at the N terminus of CR1 (Fig. 1) and demonstrated that
PfRh4 binding suppresses decay-accelerating activity of Site 1,
but not binding to C4b (20, 21). In the current study, we sought
to confirm that no other regions of CR1 are involved in binding
to PfRh4, and we asked whether all three of the N-terminal
CCPs are required for PfRh4 binding. To address these issues,
we expressed a variety of CR1 truncation constructs in 293T
cells and assessed the ability of the resultant proteins to bind
PfRh4 in anELISA-based assay.We first prepared LHRsA, B, C,
and D (CR1 1–7, CR1 8–14, CR1 15–21, and CR1 22–30,
respectively) and then assessed their binding to PfRh4 (Fig. 2,A
and B). As expected (21), only LHR A bound to PfRh4 in this
assay. We then deleted CCP 1, 2, or 3 from LHR A (LHR A 1,
FIGURE 1. Schematic representation of CR1. Themost common allelic formof CR1 contains 30 extracellular CCPs followedby a transmembrane domain (TM)
of 28 amino acid residues and a cytoplasmic tail (CYT) of 43 residues. Based on homology, the first 28 CCPs are further grouped into LHRs A, B, C, and D. LHR A
(CCPs 1–7) contains a C4b-binding site and possesses decay-accelerating activity (site 1, CCPs 1–3 in yellow), whereas LHRs B (CCPs 8–14) and C (CCPs 15–21)
each contain site 2 (duplicated functional units CCPs 8–10 and15–17 inpurple) that are 99% identical, bindC3b andC4b, andhave factor I cofactor activity. The
binding site for PfRh4 was previously mapped to CCPs 1–3 in LHR A (yellow ovals) (21). LHR D refers to LHR D plus CCPs 29 and 30.
FIGURE 2. CCP 1 in LHR A is essential for PfRh4 binding. Microtiter plates
were coated with PfRh4 (0.5 g/well). The interaction between CR1 protein
constructs in the supernatants of transfected HEK 293T cells and PfRh4 was
detectedbya rabbit anti-CR1polyclonalAb.A, only LHRAshowsbinding.B, in
LHR A, deletion of CCP 1 abrogates PfRh4 binding, whereas deletion of CCP 2
or 3 has no effect. Displayed values are the means  S.E. of at least three
independent experiments in this figure and in Figs. 3 and 4.
Binding Site of Malaria PfRh4 on Complement Receptor 1
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LHR A 2, and LHR A 3) and observed that the protein lack-
ing CCP 1 did not bind detectably to PfRh4 (Fig. 2B), whereas
proteins lacking CCP 2 or 3 bound normally. Thus, PfRh4
requires CCP 1 for binding to CR1; this is probably the most
membrane-distal of the 30 CCPs in the extracellular domain of
CR1.
Two Amino Acids in CCP 1 Are Essential for PfRh4 Binding—
CCP1 has 55% sequence identity with both CCPs 8 and 15,
which are 100% identical with one another (36, 37). Because
CCP1 is necessary for binding to PfRh4, whereasCCPs 8 and 15
in LHRs B and C, respectively, do not contain a PfRh4-binding
site, we hypothesized that it might be possible to use homolo-
gous substitutionmutagenesis tomapmore precisely the PfRh4
interaction. A similar exercise had previously achieved the
delineation of C4b-binding and C3b-binding sites (39–44).
Using the 27 amino acid residues that differ between the
sequences of CCP 1 and CCP 8 (Fig. 3A) as an initial template
for mutations, we substituted individual or clusters of amino
acid residues from CCP 8 (Fig. 3B) into their homologous posi-
tion(s) in CCP 1. These mutations (m) were named after their
positions in CCP 1. For instance, the double mutant Q1H,N3Q
was namedm1,3.
The mutants were assessed for their ability to bind to PfRh4.
For these experiments, LHR A was employed as a positive con-
trol, and LHR B was employed as a negative control. Of the 13
LHRAmutants tested (Fig. 3B),m18,19 andm20,21 showed the
most striking decrease in binding. Themutantsm6–9 andm35
also exhibited a significant (60%) loss of affinity for PfRh4
compared with native LHR A. To further identify the exact
residues that are required for binding, we mutated each indi-
vidual amino acid residue in m6–9, m18,19, and m20,21 (Fig.
3C). We found that m18 and m20 abrogated PfRh4 binding,
whereas m19 and m21 showed substantially reduced binding.
Within the other region investigated, i.e., m6–9, the results of
FIGURE 3. Identification of amino acid residues in CCP 1 important for PfRh4 binding. A, the 27 amino acid residues that differ between CCP 1 and CCP 8
are marked with braces. Because LHR B does not bind to PfRh4, amino acid residues in CCP 1 were substituted with their equivalents in CCP 8. Numbers
following the “m” (formutant) denote the position of substituted amino acids; i.e.,m1,3has both theQ1H andN3Qmutations in LHRA. B,m18–19 andm20–21
show negligible binding to PfRh4, whereasm6–9 andm35 display a50% reduction in binding. All others are not significantly different from LHR A. C, amino
acid residues Asp18 and Phe20 are essential for PfRh4 binding. Single amino acid substitutions were prepared in the LHR A template, and the proteins were
tested for alterations in binding to PfRh4. Experimental design as in Fig. 2 including the use of supernatants of transfected HEK 293T cells containing the CR1
proteins.
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single-residue replacements were not as clear; in this case,m7,
m8, and m9 individually had a more modest effect on binding
comparedwith the large effect of the simultaneous replacement
of all four residues. On the other hand, a mutant of LHR A,m6,
carrying the single amino acid substitution E6D from LHR B
bound to PfRh4 severalfold better than the native protein.
Conversion of LHR B to a PfRh4 Binding Site—By using
reverse homologous substitutionmutagenesis (i.e., substituting
PfRh4-interacting amino acids residues from CCP 1 into CCP
8), we sought to create a PfRh4-binding site in LHR B (Fig. 4).
The resultant LHR B mutants were named m18,20r or m18–
21r, etc., to reflect the sequence numbers of the CCP 1 residues
that replaced residues in homologous positions within LHR B.
The double substitution of Asp18 and Phe20 into their appropri-
ate positions in LHR B (replacing Asn468 and Ser470, respec-
tively, in the context ofm18,20r orm18–21r) was not sufficient
to confer a PfRh4 binding capability on LHR B. Likewise, sub-
stitution of four residues to create m7–9,35r did not alone
result in any measurable affinity for the parasite protein. How-
ever, if the six LHR A (CCP 1) amino acids (namely 7–9 and
18–20)were simultaneously substituted into LHRB, the result-
ant mutant (m7–9,18–20r) bound PfRh4 16-fold better than
LHR A (Fig. 4). The additional substitution of a Gly with Glu at
position 35 (as inm7–9,18–20,35r) reduced PfRh4 binding, but
it was still severalfold better than LHRA. Taken together, these
data provide strong evidence for the presence of a binding site
on CCP 1, in functional Site 1 of CR1, primarily comprised of
residues 7–9 and 18–20.
Immunoprecipitation Experiments Confirm Mutational
Analyses—The recombinant proteins LHR A, LHR B, and LHR
A1 (i.e., CCPs 2–7) and the mutant m7–9,18–20r were indi-
vidually incubated with PfRh4 and then immunoprecipitated
using either a monoclonal Ab to CR1 (J3B11) or a monoclonal
Ab to PfRh4 (10C9) (Fig. 5). Western blots of the eluants were
evaluated for CR1 using a polyclonal anti-CR1 and for PfRh4
using a polyclonal anti-PfRh4 antibody. We observed that
LHR A and m7–9,18–20r co-immunoprecipitated with
PfRh4, whereas LHR B and LHR A1 did not (Fig. 5A). The
results also showed that, as expected, m7–9,18–20r was
more efficiently pulled down with PfRh4 compared with
LHR A. In our reciprocal immunoprecipitation experiments
using anti-CR1 mAb J3B11, we observed that PfRh4 inter-
acted with LHR A and m7–9,18–20r, but not with LHR B or
LHR A1, consistent with the results above (Fig. 5B). Fur-
thermore, more PfRh4 co-precipitated with m7–9,18–20r
than with LHR A itself. These results are in agreement with
the ELISA data.
Surface Plasmon Resonance Characterization of the PfRh4:
CR1 Interaction—We first examined the binding of PfRh4 to
immobilized LHRA, LHRB, and LHRD (Fig. 6). As anticipated,
PfRh4 bound in a dose-dependent fashion to LHR A, whereas
there was no detectable binding to LHR B or LHRD. The KD of
PfRh4 binding to immobilized LHRAwas 490 60 nM (Fig. 6B
is a representative example). We next assessed binding of LHR
A and LHRB and selectedmutants, this time employing immo-
FIGURE 4. A PfRh4 binding capability can be conferred upon LHR B. The
two amino acid residues in CCP 1 whose replacement had been shown to
abrogate binding were first substituted into LHR B at their homologous
positions (m18,20r) but were not sufficient to confer PfRh4 binding. Other
mutations that decreased binding of LHR A were also substituted into
m18,20r. m7–9,18–20,35r bound 3-fold better than LHR A. m7–9,18–20r
bound 16-fold better than LHR A. On the other hand, m7–9,35r did not
bind. The experimental design for this figure was similar to that in Figs. 2
and 3, except that the CR1 proteins were His-tagged and purified from the
supernatants.
FIGURE 5. LHR A and m7–9,18–20r co-immunoprecipitate with PfRh4.
Co-IP experiments were performed by mixing a CR1 variant in the superna-
tant of HEK 293T transfectants with PfRh4 and then incubating with protein
A/G-agarose beads bearing either anti-CR1 monoclonal Ab J3B11 or anti-
PfRh4 monoclonal Ab 10C9. A, Western blot analysis of eluants from IP with
10C9 using polyclonal anti-CR1 Ab. The first four lanes (controls) show LHR A,
LHR B, LHR A 1, and m7–9,18–20r, whereas the last four lanes contain the
eluants of IP with 10C9. LHR A (lane 5) andm7–9,18–20r (lane 8) co-IP with
PfRh4, whereas LHR B (lane 6) and LHR A1 (lane 7) do not. B, Western blot
analysis of eluants from IP blotted with J3B11 shows that PfRh4 co-IP with
LHR A (lane 2) and m7–9,18–20r (lane 5) but not with LHR B (lane 3) or LHR
A 1 (lane 4).
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bilized PfRh4 (Fig. 7). The LHR B mutant carrying the six CCP
1 amino acid substitutions, m7–9,18–20r, bound many-fold
better than LHR A. On the other hand, LHR A lacking CCP 1
did not bind detectably, and neither did the mutants m18 and
m20. These observations are in accord with the ELISA and IP
results.
In further experiments, LHR A, sCR1, and m7–9,18–20r
were passed over immobilized PfRh4 to obtain quantitative
affinities (Fig. 8). Dissociation constants were calculated from
Req values derived from the resulting reference-subtracted
curves and fitted to a Langmuir 1:1 interaction model. The KD
of sCR1 binding to PfRh4 was estimated to be 8  1 M,
whereas that of LHRA binding to PfRh4was 2 1M, which is
somewhat weaker thanwhen this experiment was performed in
reverse (i.e., when LHR A was immobilized and PfRh4 passed
over the chip; KD  490 nM) (Fig. 6). Strikingly, the estimated
KD form7–9,18–20r passed over immobilized PfRh4 was 61
9 nM. This is an 30-fold higher affinity than LHR A and is
consistent with the ELISA and IP results.
In prior studies of CR1 employing affinity chromatography
with C3b or C4b Sepharose beads, we more efficiently isolated
CR1 in solubilized cell extracts if a low salt (50 or 75 mM)
buffer was used (56). To further investigate this ionic
strength dependence, we passed sCR1, LHR A and
m7–9,18–20r over immobilized PfRh4 at 75, 150, and 300
mM salt (Fig. 9). Consistent with the previous data, the affin-
ities of all three analytes were many-fold higher at 75 mM
NaCl compared with 150 mM NaCl, whereas there was no
detectable binding at 300 mM. These data support the
hypothesis that the PfRh4 interaction with CR1 also has a
major electrostatic component.
Visualizing the PfRh4 Binding Site of CR1 1–3 in Three-di-
mensional Solution Structure—The three-dimensional solu-
tion structure of CR1 1–3 was solved using a combination of
NMR and SAXS, thereby allowing visualization of the spatial
positions of themutated residues (Figs. 10 and 11). As expected
from a previous study of CR1 15–17 (74% sequence identity
with CR1 1–3) (24, 33), all three CCPs adopt a beta-sandwich-
type fold and have an ovoid appearance. Two disulfide bridges
within each CCP form the boundaries of a hydrophobic core
containing conserved lipophilic side chains, whereas loops and
turns contain conserved glycine and proline residues. In each
CCP, the N and C termini lie at opposite ends of the long axis,
and the three CCPs form an extended structure with small
interfaces (and a few NOEs; Table 1) between modules (Fig.
10). This highly elongated shape is consistent both with
intermodular flexibility and with the possibility of CCP 1
being projected well clear of the glycocalyx and accessible for
binding by PfRh4.
FIGURE 6. PfRh4 binds to immobilized CR1 LHR A. A, PfRh4 was injected at 5.5, 2.8, 1.4, 0.7, 0.35, and 0.18 M over parallel flow cells of nickel-purified,
surface plasmon resonance chip immobilized LHR A (3,000 RU), LHR B (3,600 RU), and LHR D (3,800 RU). The reference-subtracted sensorgrams
demonstrate concentration-dependent binding to LHR A. No binding of PfRh4 to LHR B or LHR Dwas detected. B, the PfRh4:LHR A binding data conform
to a 1:1 Langmuir interaction model. A nonlinear regression of response units versus PfRh4 concentrations demonstrate a KD (indicated by a dotted line)
of 490  60 nM.
FIGURE 7.Mutations in CCP 1 of CR1 abrogate PfRh4 binding. A, supernatants containing His-tagged CR1 recombinant constructs were injected at 220 nM
over immobilized PfRh4 (3,300 RU). Reference subtracted sensorgrams demonstrate that LHR A 1, m18, and m20 behave like LHR B and do not bind to
immobilized PfRh4. A parallel flow cell bearing 4,000 RU immobilized mouse IgG was employed as the reference. B, duplicate injections of supernatants
containing His-tagged constructs passed over immobilized PfRh4 demonstrate that m7–9,18–20r carrying six single amino acid substitutions from LHR A
confers a PfRh4-binding site if placed in homologous positions of LHR B. Consistent with ELISA and IP results, m7–9,18–20 protein has a many-fold greater
affinity for PfRh4 than LHR A.
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The three residues whose individual substitution had the
largest effects on PfRh4 binding, Glu6 (3.5-fold increase when
changed to Asp), Asp18 (no binding when changed to Asn), and
Phe20 (no binding when changed to Ser) are all surface-exposed
and lie close together on CCP 1 (Fig. 11). Likewise, residues 7–9
and 18–20, which upon incorporation intoCCP 8 create a PfRh4-
binding site, form a contiguous CCP 1 surface patch. Thus, the
mutagenesis experiments identified a feasible and highly accessi-
ble PfRh4-binding site lying to the side of CCP 1 and well away
from its interfacewithCCP2; this includes all orpart ofTrp7 along
with Phe20 and surrounding negative charges.
DISCUSSION
The binding of parasite ligand PfRh4 to CR1 mediates an
important mode of entry for malaria parasites into human
erythrocytes. By combining homology-guided mutagenesis
with quantitative assays of protein-protein interactions and
solution-structure determination, wemapped the PfRh4-inter-
acting region onCR1. It lies entirely within theN-terminal CCP
(CCP1), which is potentially furthest from themembrane of the
30 tandem CCPs that comprise the highly extended extracellu-
lar domain of the most common size variant of CR1.
The functionally critical nature of a small number of individ-
ual residues with surface-exposed side chains on CCP 1 helped
to delineate the PfRh4-binding site. ThemutationW7H in LHR
A (m7) halved the affinity of LHR A for the parasite ligand,
whereas L8F and P9L had little effect, despite the drastic loss of
activity when all three were mutated together (along with E6D)
(i.e., in LHR A m6–9). Neither D18N (m18) nor F20S (m20)
versions of LHR A retained any detectable affinity for PfRh4,
whereas D6E LHRA (m6) exhibited a greatly enhanced affin-
ity. Because both host and parasite are evolving, we would
FIGURE8.PfRh4 interactionswith sCR1, LHRA, andm7–9,18–20r.CR1 constructswere injected atmultiple concentrations over surface plasmon resonance
chip immobilized PfRh4 (850 RU). A parallel flow path bearing 630 RU of immobilized mouse IgG was used as a reference. Dissociation constants were
calculated from Req values derived from reference-subtracted curves and fitted to a Langmuir 1:1 interactionmodel.A, sCR1was injected at 10, 6.7, 3.3, 2.2, 0.7,
0.2, and 0.08M. The KD (indicated by a dotted line) was calculated to be 8 1M. B, supernatants from transfected 293T containing LHR Awere injected at 5,
1.7, 0.6, 0.2, and 0.1M. KD 2 1M. C, supernatants from transfected 293T cells containing them7–9,18–20r protein were injected in duplicate at 250, 128,
64, 32, and 17 nM. KD 61 9 nM,30-fold greater than that observed for PfRh4:LHR A.
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not expect the CR1:PfRh4 protein-protein interface to have
been optimized by natural selection. That replacement of
Glu6 by an Asp significantly improves binding is therefore
not surprising; rather it reinforces our hypothesis that Glu6,
along with Asp18 and Phe20, contributes to binding of PfRh4
and suggests that the carboxyl group of the shorter side chain
is better placed to form a salt bridge with an electropositive
group on PfRh4. Note that none of these homologous sub-
stitutions are likely to have disturbed the structure of CCP 1,
given the high structural similarity evident between the rel-
evant regions of CCP 1 (solved in this study) and CCP 8
(modeled on the structure of CCP 15 that is 100% identical in
sequence to CCP 8).
Although G35E had decreased affinity for PfRh4, this proba-
bly does not reflect its direct contribution to a PfRh4-binding
site. Gly occurs at equivalent positions in all of the CCPs of CR1
with the exception ofCCPs 7 (and nearly identical CCP14, CCP
21, and CCP 28) and CCP 8 (and nearly identical CCP 15). The
same G35E mutation also disrupts C4b binding and decay-ac-
celerating activity in the construct LHR A (39, 43). Gly35 occu-
pies a loop ofCCP1 that contactsCCP2, and its replacement by
Glu in CCP 8 could help to explain the differences in inter-
module angles that are apparent from a comparison of CR1
1–3 and CR1 15–17 structures. In sum, Gly35 is thought
more likely to have an architectural role rather than being
involved directly in binding.
The substitution of Asp18 and Phe20 (individually critical for
PfRh4 binding inCCP 1 as discussed above) and the glutamates at
positions 19 and 21 into their homologous positions in CCP 8 of
LHRB (creating,m18–21r) was not sufficient to facilitate binding
of themutantLHRBtoPfRh4 (Fig. 4).On theotherhand, aPfRh4-
binding mutant of LHR B was successfully created when three
further CCP 1 amino acid residues (Trp7, Leu8, and Pro9) were
additionally substituted into CCP 8 at their homologous positions
(although in this caseAsp471, equivalent toGlu21,wasunchanged).
Both Leu8 and Phe458 are buried in their respective modules, so
this substitution is a conservativeone, andweassume thisdoesnot
affect function. As mentioned, W7H (inm7) reduced binding by
only 50%, so it appears that the imidazole side chain of His can
substitute partially for the indole ring ofTrpprovidedPro9 is pres-
ent; in the context of P9L, however, the His side chain has swung
out as may be observed in CCP 8 (Fig. 11), and it can no longer
perform this surrogate role. The additional substitution of Glu458
with Gly35 in CCP 8 led to a reduction in binding (i.e., when
m7–9,18-20 is compared with m7–9,18–20,35r), supporting the
idea that Gly35 is not part of the primary binding site of PfRh4 on
CR1. Unsurprisingly, m7–9,35r (lacking substitution by residues
18–20) did not bind to PfRh4.
FIGURE 9.CR1 interactionwithPfRh4 is ionic strength-dependent. Supernatants containing sCR1, LHRA, andm7–9,18–20rwere injectedover immobilized
PfRh4 in 75, 150, or 300 mM NaCl buffer. A–C, representative reference-subtracted sensorgrams are presented for each protein: sCR1 (A), LHR A (B), and
m7–9,18–20r (C).
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All of these results were combined with knowledge gained
from the newly determined structure of CR1 1–3 (Fig. 11) to
infer the location and extent of the PfRh4-binding site.We pro-
pose that it includes the surface-exposed Phe20, four surround-
ing residues with electronegative side chains (Glu6, Asp18,
Glu19, and Glu21), and all or part of Trp7. Thus, four of six
FIGURE 10. Summary of NMR/SAXS-derived structures. Ensembles (for the 20 lowest energy structures) are shown as overlaid backbone traces; the root
mean square deviation (heavybackbone atoms) value is shown for eachoverlay. Closest tomean structures are drawnas cartoons (PyMOL) basedon-strands
determined by STRIDE (65), and cysteine sulfur atoms are drawn as spheres. A, ensemble for CR1 1–2. Upper left, overlay on module 1; upper right, overlay on
module 2; lower left, overlay on both modules; lower right, closest to mean structure. B, ensemble for CR1 2–3. Upper left, overlay on module 2; upper right,
overlay on module 3; lower left, overlay on both modules; lower right, closest to mean structure. C, ensemble for CR1 1–3. Top, from left to right, overlays on
modules 1, 2, and 3; bottom left, overlay on all modules; bottom right, closest to mean structure.
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negatively charged amino acid side chains of CCP 1 lie in the
putative PfRh4-binding site, whereas the 88-kDa region of the
recombinant PfRh4 protein used in these experiments has a
very basic pI of 8.9.We showed that the CR1/PfRh4 interaction
is sensitive to high ionic strength, supporting the notion that
electrostatic forces including salt bridges are crucial to recep-
tor-ligand engagement. Strikingly, if these putative binding site
residues are collectively substituted into their equivalent posi-
tions within CCP 8, the product is a version of LHR B that has a
high affinity for PfRh4; this convincingly confirms our identifi-
cation of the PfRh4-binding site in CCP 1 of CR1. The residues
thought to form the PfRh4-binding site on CCP 1 do not partici-
pate in the junction with CCP 2 and are also distant from other
residues that were identified in a previous study as important for
binding byCR1 1–3 toC4b (40). This is consistent with our previ-
ous demonstration of the formation of a C4bPfRh4CR1 1–3 ter-
nary complex. Interestingly, one of the binding site residues, Trp7,
was shown (43) to be required for decay-accelerating activity that
probably involvescontactsbyCR1functional site1withbothcom-
ponents of the convertases, i.e., Bb aswell as C3b in the alternative
pathway or C2a as well as C4b in the classical pathway. The par-
ticipation of this putative residue in the Bb/C2a and PfRh4-bind-
ing site could explain why PfRh4 blocks the decay-accelerating
activity of CR1 1–3 (21).
The discovery that the LHR B mutant, m7–9,18-20r, binds
nearly 30-fold better to PfRh4 than LHR A could potentially
lead to an inhibitor of parasite invasion. Experiments to deter-
mine whether this construct blocks the PfRh4-CR1 merozoite
invasion pathway of erythrocytes are in progress. It would also
be of interest to determine whether insertion of these muta-
tions into the CR1 protein enhances the ability ofmerozoites to
invade erythrocytes (i.e., increases parasite virulence). How-
ever, it is possible that there is a level of PfRh4 affinity for CR1
that is sufficient for its role in invasion, and increased ability to
bind may not increase its function.
The structure of PfRh4 is not known, and there are no reports
of its successful crystallization. The formation of a complex of
PfRh4 with the high affinity CR1 mutant m7–9,18–20r might
facilitate crystal formation and subsequent structure determi-
nation. This could provide information that would be of use for
the design of a highly efficacious component of a multicompo-
nent vaccine that would include a combination of blood stage
antigens to protect against disease and interrupt transmission
of P. falciparum (57).
The evolution of parasite-host relationships is greatly
intriguing. Themalaria parasite uses erythrocyte invasion path-
ways that involving binding to glycophorins, which are likely to
be ancient in origin because there has been significant negative
pressure on human populations living in malaria endemic
areas. For example, there aremutations in glycophorins B andC
that have been associatedwith alterations inmalarial severity or
susceptibility (17, 58–62). Such mutations likely favored the
use of other pathways in which a merozoite adhesin binds to
different erythrocyte receptor, e.g., PfRh4:CR1. Both laboratory
FIGURE 11. Identification of the PfRh4-binding site in CCP 1 of CR1. In the top left are two views of the surface of the (lowest energy) NMR-derived solution
structure of CR1 1–3. Residues of CCP 1 that are conserved in CCP 8 are inwhite; nonconserved residues that may be substituted by equivalent CCP 8 residues
without any measurable effect on PfRh4 binding are colored pink; residues substituted in the m6–9 mutant of LHR A (cyan) and in the m18,19 and m20,21
mutants (yellow) are also highlighted. Gly35 and other residues previously identified as important for C4b binding by CR1 1–3 are colored orange. Residues 6–9
and 18–21 are also shown by stick representation in the expansion (right), with carbons colored cyan and yellow (respectively), oxygens in red, and nitrogens
in blue. Asp18 and Phe20 (blue labels) are essential for PfRh4 binding; substitution of Glu6 (red label) by Asp increases binding 3-fold. In the bottom right are
shown (as sticks) the residues of CCP 8 (modeled on structure of CCP 15 that is nearly identical) equivalent to CCP 1 residues 6–9 and 18–21. Replacement of
these (in LHRB) by the equivalent CCP1 residues creates a novel, strongPfRh4-binding site in LHRB. These studies led to theproposal of thebinding site shown
in the bottom left. The surface here is cut away to reveal atom representations of Trp7 as well as Phe20 and the surrounding negatively charged side chains of
Glu6, Asp18, Glu19, and Glu21 (colored as in the stick representation).
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and field P. falciparum isolates with differing dependences on
CR1 or glycophorins have been described, but notably, some
P. falciparum lines can activate PfRh4 expression to switch
receptor usage (63, 64). This is an example of phenotypic vari-
ation that provides a means for the malaria parasite population
to vary its ligand receptor usage in the face of selective pressures
from the host. Interestingly, SNPs in the putative PfRh4 binding
site in CCP 1 of CR1 have not been reported in the 1,000-ge-
nome database, suggesting either that this is amore novel path-
way or possibly that this binding site serves a crucial host CR1
function. Our results favor the latter possibility and are consist-
ent with this being the decay-accelerating activity of func-
tional Site 1 and specifically (because these residues are not
needed for C3b/C4b binding) an important contact between
CCP 1 and the C3 and C5 convertases. Mutations of at least
some of these critical CR1 residues might thus be selected
against, even in malaria-endemic populations.
In conclusion, our studies have identified a site in CR1 that
the P. falciparum merozoite utilizes for erythrocyte invasion.
These studies provide newunderstanding at themolecular level
that may assist in development of future therapeutics.
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TABLE 1
Summary of statistics gathered for ensembles of CR1 1,2, CR1 2,3, and CR1 1–3
The root mean square deviation values were calculated using segments between the first and fourth consensus Cys residues in a given module. The NOE categories were:
sequential, residue i	 residue i 1; medium range, residue i	 residue (i (2–4)); long range, residue i	 residue (i (4)). Tilt, twist, and skew angles were calculated
using a describedmethod (48). PROCHECK-NMR (66) software was used to derive the Ramachandran statistics. The areas of buried surfaces were calculated using the “get
area” function in PyMOL (67).
CR1 1,2 CR1 2,3 CR1 1–3a
Completeness of assignment
15N (excluding Pro) 100% 94%
1H(N) 100% 94%
13C(O) 95% 94%
13C() 98% 95%
13C() 99% 95%
1H() 98% 95%
1H() 88% 95%
NOE statistics
Intraresidue/sequential 507/724 468/620 708/1,012b
Medium/long range 348/999 203/950 427/1,458b
Total 2578 2241 3,605b
Intermodular 3 10
CCP 1 to linker 44
CCP 2 to linker 85 89
CCP 3 to linker 51
RMSD values (Å) (superposition using heavy backbone
atoms; mean S.D.)
CCP 1 0.72 0.12 0.73 0.13
CCP 2 0.75 0.14 0.75 0.14 0.88 0.19
CCP 3 1.21 0.28 0.93 0.15
CCP 1 CCP 2 1.05 0.17 1.04 0.18
CCP 2 CCP 3 1.31 0.25 1.10 0.21
CCP 1 CCP 2 CCP 3 1.15 0.19
CCP 1-CCP 2 CCP 2-CCP 3
Intermodular angles (°) and buried surface area
(Å2; mean S.D.)
Tilt 50 4 64 3 50 2 60 3
Skew 92 9 	59 9 90 7 	44 8
Twist 107 4 85 3 106 3 76 2
Buried surface area 163 51 515 72 151 48 469 52
Ramachandran assessment (%)
Most favored 81.1 81.4 79.1
Additionally allowed 14.7 13.0 14.4
Generously allowed 2.0 3.0 4.5
Disallowed 2.2 2.6 2.0
a Calculated by concatenating NMR-derived data for CR1 1,2 and CR1 2,3 along with SAXS-derived data for CR1 1–3; the overall  values calculated for the fittings across
the 20 refined structures of CR1 1–3 were 1.45 0.04.
b Derived from the NOE lists for CR1 1,2 and CR1 2,3 as described in text (i.e., not from NMR spectra collected on CR1 1–3).
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